Hoth Therapeutics Inc

Hoth Therapeutics Inc. a clinical-stage biopharmaceutical company focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001 a topical formulation which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis as well as inflammatory bowel diseases; and HT-002 a novel peptide for treating COVID-19. The company is also developing BioLexa Platform a proprietary patented drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences Inc. and the University of Cincinnati; Zylö Therapeutics Inc.; and Voltron Therapeutics Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics Inc. was incorporated in 2017 and is based in New York New York.